Composition helpful for regulating enteric microorganisms of adult dogs, combined fiber sheet and application of composition and combined fiber sheet

Abstract

The invention provides a composition helpful for regulating intestinal microorganisms of adult dogs, a combined fiber sheet and application of the composition and the combined fiber sheet, and belongs to the technical field of animal intestinal regulators. The composition comprises the following components: pea dietary fibers, citrus dietary fibers, an avocado extract, oat dietary fibers and seaweed dietary fibers. The composition can regulate intestinal flora of the adult dogs and is beneficial to intestinal health of the adult dogs. By supplementing the composition rich in dietary fibers, the adult dogs can regulate and support symbiotic microbial communities living in digestive tracts, the composition and diversity of intestinal microbiota and the physiological functions of hosts are improved, and further, by increasing the diversity and functions of the intestinal microbiota, such as the ability to produce short-chain fatty acids, the immunity of the adult dogs is improved. And healthy intestinal microbiota can be maintained.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of animal intestinal regulator, and particularly relates to a composition for regulating intestinal microorganisms of adult dogs, a combined fiber tablet and application thereof. BACKGROUND

[0002] Cellulose was once considered to be a substance without any nutritional value for both human food and pet food, but with the deepening understanding and continuous exploration of food nutrition science and pet nutrition, cellulose is more and more accepted and recognized. With the progress of pet nutrition technology, cellulose is gradually accepted as a new type of nutrient and added to the team of nutritional elements, becoming the "seventh nutrient element" without doubt.

[0003] As an effective nutrient for preventing diarrhea of dogs, cellulose is mainly applied in dog food. In the gastrointestinal tract of dogs, cellulose is beneficial to the decomposition and combination of Escherichia coli into various vitamins, greatly reducing the symptoms such as pet diarrhea caused by Escherichia coli. In addition, cellulose can also adsorb a large amount of water in the intestinal tract of dogs, promoting the health of the gastrointestinal tract of dogs. Cellulose can promote intestinal peristalsis of dogs, accelerate the excretion of feces, make various harmful substances discharged from the body in the shortest time, reduce the residence time of harmful substances in the intestinal tract, and reduce the adverse stimulation to the intestinal tract, thereby preventing the occurrence of intestinal diseases of dogs.

[0004] There are many foods containing cellulose nutrients, but not all cellulose nutrients can be utilized by dogs, and there is no related food research and development in the current pet food industry. SUMMARY

[0005] The present application provides a composition for regulating intestinal microorganisms of adult dogs, a combined fiber tablet and application thereof. The composition and the combined fiber tablet can be utilized by dogs, used for regulating intestinal flora of adult dogs, and beneficial to the health of the intestinal tract of adult dogs.

[0006] The present application provides a composition for regulating intestinal microorganisms of adult dogs, comprising the following components in parts by weight: 10-30 parts of pea dietary fiber, 10-30 parts of citrus dietary fiber, 10-20 parts of avocado extract, 2-30 parts of oat dietary fiber and 10-15 parts of seaweed dietary fiber.

[0007] Preferably, the composition comprises the following components in parts by weight: 15-20 parts of pea dietary fiber, 15-20 parts of citrus dietary fiber, 12-18 parts of avocado extract, 17-18 parts of oat dietary fiber and 12-13 parts of seaweed dietary fiber.

[0008] Preferably, the composition further comprises: 2-5 parts of lycopene and 3-6 parts of vitamin C.

[0009] Preferably, the pea dietary fiber includes pea dietary fiber powder; the citrus dietary fiber includes citrus dietary fiber powder; and the particle sizes of the pea dietary fiber powder and the citrus dietary fiber powder are independently 180 to 240 μm.

[0010] The present invention also provides a combined fiber sheet that helps regulate intestinal microorganisms in adult dogs, comprising the composition described in the above scheme and auxiliary materials; based on 10 to 30 parts of pea dietary fiber, the auxiliary materials preferably include: 2 to 20 parts of glucose and 2 to 5 parts of edible flavoring.

[0011] The present invention also provides the use of the composition described in the above scheme or the combined fiber sheet in the preparation of products for regulating intestinal microorganisms of adult dogs and / or improving the growth status of adult dogs; the products include feed, feed additives, nutritional supplements or medicines.

[0012] Preferably, the regulation of intestinal microorganisms of adult dogs includes one or more of the aspects 1) to 3):

[0013] 1) Increase the abundance of beneficial intestinal bacteria;

[0014] 2) Improve the fecal status of adult dogs;

[0015] 3) Improve the fecal odor of adult dogs.

[0016] Preferably, the beneficial bacteria include one or more of the family Lachnospiraceae, the family Erysipelotrichaceae and the genus Blautia.

[0017] The present invention also provides use of the composition or the combined fiber sheet described in the above scheme in the preparation of a drug for preventing and / or treating inflammatory bowel disease in adult dogs.

[0018] Preferably, the prevention and / or treatment of inflammatory bowel disease in adult dogs includes one or more of the aspects (1) to (4):

[0019] (1) Reduce intestinal inflammation levels;

[0020] (2) Repair intestinal mucosal damage;

[0021] (3) Reduce oxidative stress in the intestine;

[0022] (4) Increase the content of short-chain fatty acids in the intestine.

[0023] The present invention provides a composition that helps regulate the intestinal microorganisms of adult dogs, comprising the following components: pea dietary fiber, citrus dietary fiber, avocado extract, oat dietary fiber, and seaweed dietary fiber. The composition of the present invention can regulate the intestinal flora of adult dogs and is beneficial to the intestinal health of adult dogs. By supplementing with the dietary fiber-rich composition of the present invention, adult dogs can regulate and support the symbiotic microbial communities residing in the digestive tract. Citrus dietary fiber and avocado extract are low in fiber, while pea dietary fiber, oat dietary fiber, and seaweed dietary fiber are high in fiber. The combined intake of low-fiber and high-fiber can improve the composition, diversity, and physiological function of the intestinal microbiome. A diet rich in dietary fiber maintains a healthy intestinal microbiome by increasing the diversity and function of the intestinal microbiome, such as the ability to produce short-chain fatty acids. Therefore, the intestinal flora regulating effect of the composition of the present invention was verified by experimentally measuring the production of short-chain fatty acids. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0025] Figure 1 To test the weight growth of dogs for safety;

[0026] Figure 2 Stool scoring sheet;

[0027] Figure 3 Scoring the feces of dogs for safety testing;

[0028] Figure 4 The weight growth of the experimental dogs;

[0029] Figure 5 Scoring the feces of the test dogs;

[0030] Figure 6 To test the dog feces odor;

[0031] Figure 7 The data of intestinal inflammation index of the experimental dogs on day 42;

[0032] Figure 8 This is the SCFAs index data of the experimental dogs on day 42;

[0033] Figure 9 This is the phylum-level microbial sequencing result;

[0034] Figure 10 This is the family-level microbial sequencing result;

[0035] Figure 11 The results of microbial sequencing at the genus level. DETAILED DESCRIPTION

[0036] The present invention provides a composition that helps regulate intestinal microorganisms in adult dogs. The composition comprises the following components in parts by weight: 10 to 30 parts of pea dietary fiber, 10 to 30 parts of citrus dietary fiber, 10 to 20 parts of avocado extract, 2 to 30 parts of oat dietary fiber and 10 to 15 parts of seaweed dietary fiber.

[0037] In the present invention, the composition includes 10 to 30 parts of pea dietary fiber, preferably 15 to 20 parts, and more preferably 18 parts, by weight; the pea dietary fiber preferably includes pea dietary fiber powder; the particle size of the pea dietary fiber powder is preferably 180 to 240 μm, more preferably 200 μm; the pea dietary fiber powder is preferably purchased from Xi'an Jinshuo Fruit Industry Co., Ltd.; in the present invention, the function of the pea dietary fiber powder is to provide dietary fiber, reduce the burden on the gastrointestinal tract, and accelerate gastrointestinal motility.

[0038] In the present invention, the composition includes 10 to 30 parts of citrus dietary fiber, preferably 15 to 20 parts, and more preferably 18 parts, by weight; the citrus dietary fiber includes citrus dietary fiber powder; the particle size of the citrus dietary fiber powder is preferably 180 to 240 μm, more preferably 200 μm; the citrus dietary fiber is preferably purchased from Xi'an Weisbo Biotechnology Co., Ltd.; in the present invention, the role of the citrus dietary fiber is to provide dietary fiber, which helps to increase the volume of intestinal contents and promote intestinal peristalsis.

[0039] In the present invention, the composition includes 10 to 20 parts of avocado extract, preferably 12 to 18 parts, and more preferably 15 parts, by weight; the avocado extract is preferably purchased from Shaanxi Guanchen Biotechnology Co., Ltd.; in the present invention, the function of the avocado extract is to provide dietary fiber and unsaturated fatty acids, which help promote intestinal motility and lower cholesterol.

[0040] In the present invention, the composition includes 2 to 30 parts of oat dietary fiber, preferably 17 to 18 parts, by weight; the oat dietary fiber is preferably purchased from Shandong Chuangyuan Biotechnology Co., Ltd.; in the present invention, the role of the oat dietary fiber is to provide dietary fiber, promote the growth of probiotics in the intestine, improve the intestinal microbial balance of dogs, promote the reproduction of beneficial bacteria in the intestine, improve immunity, and prevent intestinal infectious diseases.

[0041] In the present application, the composition comprises seaweed dietary fiber 10-15 parts by weight, preferably 12-13 parts; the seaweed dietary fiber is preferably purchased from Shaanxi Xutai Biological Technology Co., Ltd.; in the present application, the role of the seaweed dietary fiber is to provide dietary fiber, increase stool volume, promote intestinal peristalsis, and prevent intestinal diseases.

[0042] In the present application, the composition preferably further comprises lycopene 2-5 parts by weight, more preferably 3 parts; the lycopene is preferably purchased from Shaanxi Weipei Biological Technology Co., Ltd.; in the present application, the role of the lycopene is an antioxidant, resisting the invasion of free radicals, reducing cell damage and aging, and improving body immunity.

[0043] In the present application, the composition preferably further comprises vitamin C 3-6 parts by weight, more preferably 5 parts; the vitamin C is preferably purchased from Shandong Chuangyuan Biological Technology Co., Ltd.; in the present application, the role of the vitamin C is an antioxidant and has the effect of improving immunity.

[0044] The present application also provides a combined fiber tablet for helping to regulate the intestinal microorganisms of adult dogs, comprising the composition and adjuvants described in the above scheme.

[0045] In the present application, the adjuvants preferably comprise 2-20 parts of glucose and 2-5 parts of edible flavoring, based on 10-30 parts of pea dietary fiber; the weight of the glucose is preferably 5-10 parts; the role of the glucose is to provide energy, promote the absorption and utilization of other nutrients, and improve the taste of the cellulose tablet; the weight of the edible flavoring is preferably 4 parts; the edible flavoring is preferably purchased from Hangzhou Baile Flavor and Fragrance Co., Ltd.; the role of the edible flavoring is to improve the taste and flavor of the cellulose tablet.

[0046] In the present application, the raw materials of the combined fiber tablet preferably further comprise water and magnesium stearate; the water is used for soft material; the magnesium stearate is used as a film coating material for tabletting preparation.

[0047] In an embodiment of the present application, the combined fiber tablet is composed of the following raw materials by weight: 20 parts of pea dietary fiber powder, 20 parts of citrus dietary fiber powder, 12 parts of avocado extract, 17 parts of oat dietary fiber, 12 parts of seaweed dietary fiber, 2 parts of lycopene, 3 parts of vitamin C, 10 parts of glucose, and 4 parts of edible flavoring.

[0048] In one embodiment of the present invention, the combined fiber sheet is composed of the following raw materials in parts by weight: 18 parts of pea dietary fiber powder, 18 parts of citrus dietary fiber powder, 15 parts of avocado extract, 18 parts of oat dietary fiber, 13 parts of seaweed dietary fiber, 5 parts of lycopene, 6 parts of vitamin C, 2 parts of glucose and 4 parts of edible flavoring.

[0049] In another embodiment of the present invention, the combined fiber sheet is composed of the following raw materials in parts by weight: 15 parts of pea dietary fiber powder, 15 parts of citrus dietary fiber powder, 18 parts of avocado extract, 2 parts of oat dietary fiber, 15 parts of seaweed dietary fiber, 3 parts of lycopene, 5 parts of vitamin C, 5 parts of glucose, and 4 parts of edible flavoring.

[0050] The present invention also provides a method for preparing the combined fiber sheet described in the above scheme, comprising the following steps:

[0051] The raw materials of the combined fiber sheet described in the above scheme are mixed to obtain a mixture; the mixture is mixed with water to prepare a soft material; the soft material is sieved to obtain wet granules; the wet granules are dried to obtain dry granules; the dry granules are mixed with magnesium stearate and tableted to obtain a combined fiber sheet.

[0052] In the present invention, the mesh size of the sieve used for sieving is preferably 8 to 16 meshes; the drying temperature is preferably 40 to 70° C.; the drying time is preferably 6 hours; and the moisture content of the dried particles is preferably ≤10%.

[0053] In the present invention, the specification of the combined fiber sheet is preferably 100 mg / sheet; the dosage form of the combined fiber sheet is preferably a chewable tablet.

[0054] In the present invention, the method for using the combined fiber sheet preferably includes the following steps:

[0055] Adult dogs were fed a normal diet and a combination fiber tablet.

[0056] The present invention also provides the use of the composition described in the above scheme or the combined fiber sheet in the preparation of products for regulating intestinal microorganisms of adult dogs and / or improving the growth status of adult dogs; the products include feed, feed additives, nutritional supplements or medicines.

[0057] In the present invention, the dog preferably includes a beagle.

[0058] In the present invention, the regulation of intestinal microorganisms of adult dogs preferably includes one or more of the aspects 1) to 3): 1) increasing the richness of beneficial intestinal bacteria; 2) improving the fecal status of adult dogs; 3) improving the fecal odor of adult dogs.

[0059] In the present invention, the beneficial bacteria preferably include one or more of the family Lachnospiraceae, the family Erysipelotrichaceae and the genus Blautia.

[0060] In the present invention, when the combined fiber sheet of the present invention is used to feed adult dogs, feces are better formed, and the feces state and intestinal health of the dogs can be improved.

[0061] In the present invention, the improving the fecal odor of adult dogs preferably includes reducing the ammonia content in the feces of adult dogs.

[0062] The present invention also provides use of the composition or the combined fiber sheet described in the above scheme in the preparation of a drug for preventing and / or treating inflammatory bowel disease in adult dogs.

[0063] In the present invention, the prevention and / or treatment of inflammatory bowel disease in adult dogs preferably includes one or more of the aspects (1) to (4): (1) reducing the level of intestinal inflammation; (2) repairing intestinal mucosal damage; (3) reducing oxidative stress in the intestine; and (4) increasing the content of short-chain fatty acids in the intestine.

[0064] In the present invention, the reducing of intestinal inflammation level preferably includes reducing the content of inflammatory factors and / or anti-inflammatory factors; the inflammatory factors preferably include IL-1β and TNF-α; the anti-inflammatory factors preferably include IL-10.

[0065] In the present invention, the short-chain fatty acids preferably include one or more of acetic acid, butyric acid, and propionic acid, and more preferably include acetic acid and / or butyric acid. Acetic acid can serve as a synthetic source of butyric acid, so increased acetic acid levels can further lead to increased butyric acid content. Butyric acid has the effect of inhibiting the activation of nuclear factor κB, reducing the production of inflammatory factors, and thus alleviating local inflammatory reactions in the intestine. The combined fiber sheet of the present invention has anti-inflammatory and anti-allergic effects.

[0066] The composition or the combined fiber sheet of the present invention has no adverse effects on the body weight, intestinal tract, hematological indices and blood biochemical indices of adult dogs and is safe.

[0067] To further illustrate the present invention, a composition, a combined fiber sheet, and its application that are helpful in regulating intestinal microorganisms in adult dogs provided by the present invention are described in detail below with reference to the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0068] In the embodiments and comparative examples of the present invention, pea dietary fiber powder was purchased from Xi'an Jinshuo Fruit Industry Co., Ltd.; citrus dietary fiber was purchased from Xi'an Weisibo Biotechnology Co., Ltd.; avocado extract was purchased from Shaanxi Guanchen Biotechnology Co., Ltd.; oat dietary fiber was purchased from Shandong Chuangyuan Biotechnology Co., Ltd.; seaweed dietary fiber was purchased from Shaanxi Xupeptide Biotechnology Co., Ltd.; lycopene was purchased from Shaanxi Wopijin Biotechnology Co., Ltd.; vitamin C was purchased from Shandong Chuangyuan Biotechnology Co., Ltd.; and edible flavors were purchased from Hangzhou Bairui Flavors and Fragrances Co., Ltd.

[0069] Example 1:

[0070] Combined fiber tablets (chewable tablets) raw materials:

[0071] Pea dietary fiber powder 20g, citrus dietary fiber powder 20g, avocado extract 12g, oat dietary fiber 17g, seaweed dietary fiber 12g, lycopene 2g, vitamin C 3g, glucose 10g and edible flavoring 4g.

[0072] Production process:

[0073] (1) Mixing pea dietary fiber powder, citrus dietary fiber powder, avocado extract, oat dietary fiber, seaweed dietary fiber, lycopene, vitamin C, glucose, and edible flavoring according to the above proportions;

[0074] (2) adding a water-made soft material 5 times the mass of the mixture to the mixture obtained in step (1) under stirring conditions, and passing the obtained soft material through an 8-16 mesh sieve to obtain wet granules;

[0075] (3) drying the wet granules obtained in step (2) at 40-70° C. for 6 h to obtain dry granules;

[0076] (4) Magnesium stearate was added to the dry granules obtained in step (3), stirred evenly, and tableted to obtain combined fiber tablets (chewable tablets), each tablet containing 100 mg.

[0077] Example 2

[0078] Combined fiber tablets (chewable tablets) raw materials:

[0079] Pea dietary fiber powder 18g, citrus dietary fiber powder 18g, avocado extract 15g, oat dietary fiber 18g, seaweed dietary fiber 13g, lycopene 5g, vitamin C 6g, glucose 2g and edible flavoring 4g.

[0080] The production process is the same as that of Example 1.

[0081] Example 3

[0082] Combined fiber tablets (chewable tablets) raw materials:

[0083] Pea dietary fiber powder 15g, citrus dietary fiber powder 15g, avocado extract 18g, oat dietary fiber 2g, seaweed dietary fiber 15g, lycopene 3g, vitamin C 5g, glucose 5g and edible flavor 4g;

[0084] The production process is the same as that of Example 1.

[0085] Comparative Example 1

[0086] Ingredients for chewable tablets: carrot dietary fiber powder 15g, mulberry dietary fiber powder 15g, avocado extract 18g, oat dietary fiber 2g, seaweed dietary fiber 15g, lycopene 3g, vitamin C 5g, glucose 5g and edible flavor 4g.

[0087] The production process is the same as that of Example 1.

[0088] Comparative Example 2

[0089] Combined fiber tablets (chewable tablets) raw materials:

[0090] 10 parts pea dietary fiber powder, 10 parts citrus dietary fiber powder, 18 parts avocado extract, 2 parts oat dietary fiber, 10 parts seaweed dietary fiber, 5 parts lycopene, 10 parts vitamin C, 5 parts glucose and 4 parts edible flavoring;

[0091] The production process is the same as that of Example 1.

[0092] Test Example 1

[0093] 1) Safety test

[0094] Eighteen healthy beagle dogs weighing approximately 8.50 ± 0.01 kg were selected and divided into three groups for the experiment, as follows:

[0095] Control group: fed with normal diet;

[0096] Group 1 of Example 1: fed with a normal diet plus the combined fiber tablets of Example 1;

[0097] Group 3 of Example 3 was fed with a normal diet plus the combined fiber sheet of Example 3.

[0098] During the experiment, body weight was measured and feces were scored on days 0, 32 and 64 (see the scoring criteria for details). Figure 2 ), blood samples were collected on days 32 and 64 for biochemical and routine blood tests.

[0099] 2) Functional test

[0100] Twenty-four beagle dogs weighing 8.51 ± 0.01 kg and suffering from mild intestinal problems were divided into four groups for the experiment, as follows:

[0101] Control group: fed with normal diet;

[0102] Comparative Example 1 group: fed with normal diet plus chewable tablets of Comparative Example 1;

[0103] Comparative Example 2 group: fed with ordinary diet plus the combined cellulose tablets of Comparative Example 2;

[0104] Group 3 of Example 3 was fed with a normal diet plus the combined fiber sheet of Example 3.

[0105] During the experiment, body weight was measured on days 0, 21 and 42, and feces were collected for fecal scoring (scoring criteria see Figure 2 ), fecal odor, and on the 42nd day, fecal samples were tested for short-chain fatty acids and microorganisms in the feces, and blood was collected on the 42nd day to measure intestinal inflammation indicators.

[0106] The formal trial lasted 42 days. Weight gain and fecal status of each animal were observed on days 0, 21, and 42 after the formal trial began. On days 21 and 42 of the formal trial, 4 mL of blood was collected from the forelimb vein in a 10 mL vacuum tube. 2 mL of blood was added to a non-anticoagulant tube, and the remaining blood was allowed to stand for 30 minutes. The supernatant was then centrifuged. The supernatant was serum and stored at low temperatures. Another 2 mL of blood was added to an anticoagulant tube, the anticoagulant and blood were mixed, and the supernatant was plasma after centrifugation. Fresh feces were also collected from the animals, 3 to 5 g per sample, placed in cryopreservation tubes, and stored at low temperatures.

[0107] Detection indicators include body weight, fecal odor, fecal score, routine blood test using an automatic blood cell analyzer, blood biochemical indexes using a fully automatic biochemical analyzer, tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), lipopolysaccharide (LPS), diamine oxidase (DAO), and fatty acid binding protein (i-FABP) measured using ELISA, short-chain fatty acids measured using gas chromatography, and 16S rRNA sequencing using the Illumina Hiseq high-throughput sequencing platform to detect microorganisms in feces.

[0108] Safety test results:

[0109] Weight gain results Figure 1 As shown in Table 1:

[0110] Table 1 Weight data

[0111] index control group Example 1 group Example 3 group SEM P-value Day 0 8.51 8.50 8.50 0.01 0.69 Day 32 8.74 8.71 8.72 0.01 0.72 Day 64 9.05 9.00 9.06 0.02 0.54

[0112] Weight data is an important indicator of the growth status of pets. Figure 1As shown in Table 1, there were no significant differences among the test groups on days 0, 32, and 64 (P>0.05), indicating that neither Example 1 nor Example 3 had any adverse effects on the body weight of beagle dogs.

[0113] Evaluate according to the stool scoring table (see Figure 2 ), the results are as follows Figure 3 As shown in Table 2:

[0114] Table 2 Stool scores

[0115] index control group Example 1 group Example 3 group SEM P-value Day 0 7.95 7.63 8.07 0.10 0.21 Day 32 8.05 7.68 7.80 0.07 0.11 Day 64 7.50 7.75 7.78 0.14 0.69

[0116] Fecal score is an important indicator of dog intestinal health. Figure 3 As shown in Table 2, on days 0, 32, and 64, there were no significant differences in the fecal scores of the dogs in each example group compared with the control group (P>0.05), indicating that Example 1 and Example 3 groups had no adverse effects on the dog intestines.

[0117] Blood routine test: Use automatic blood cell analyzer to perform blood routine test.

[0118] The detection indicators mainly include: white blood cell count, lymphocyte count, lymphocyte percentage, monocyte count, neutrophil count, monocyte percentage, neutrophil percentage, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin content, mean corpuscular hemoglobin concentration, coefficient of variation of red blood cell distribution width, platelet count and mean platelet volume.

[0119] The results of hematological index tests are shown in Tables 3 and 4 below:

[0120] Table 3 Hematological parameters on day 32

[0121]

[0122]

[0123] Table 4 Hematological parameters on day 64

[0124]

[0125]

[0126] The results are shown in Tables 3 and 4: There was no significant difference (P>0.05) in the hematological indicators of the test dogs on days 32 and 64 between the control group, Example 1, and Example 3 groups, and they were at normal levels, indicating that the present invention had no adverse effects on the hematological indicators of the test dogs and was safe.

[0127] Blood biochemistry: A fully automatic biochemical analyzer was used to measure blood biochemical indicators, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting blood glucose (GLU), blood urea nitrogen (BUN), serum alkaline phosphatase (ALP), normal creatinine (Cr), total cholesterol (TCHO), total protein (TP), serum albumin (ALB), and globulin (G).

[0128] Blood biochemical indicators are shown in Tables 5 and 6:

[0129] Table 5 Blood biochemical indicators on day 32

[0130] index control group Example 1 group Example 3 group SEM P-value ALT(U / L) 35.5 34.7 35.8 2.36 0.76 AST(U / L) 33.4 33.6 36.0 2.73 0.20 GLU (mmol / L) 6.42 5.50 5.53 1.07 0.26 BUN (mmol / L) 2.77 2.53 2.53 0.34 0.42 ALP(U / L) 154 152 149 17.5 0.91 Cr (umol / L) 38.3 37.9 38.6 3.64 0.95 TCHO (mmol / L) 4.65 4.80 4.75 0.41 0.83 TP(g / L) 58.6 54.2 56.6 6.80 0.56 ALB (g / L) 22.6 23.6 22.8 1.97 0.69 G (g / L) 25.3 27.1 28.7 3.73 0.31

[0131] Table 6 Blood biochemical indicators on day 64

[0132]

[0133]

[0134] The results in Tables 5 and 6 show that at 32 and 64 days of the experiment, there were no significant differences (P>0.05) in the blood biochemical indices of the experimental dogs among the healthy group, the control group, and the Example 1 and Example 3 groups, and the blood biochemical indices were at normal levels, indicating that the present invention has no adverse effects on the blood biochemical indices of the experimental dogs and is safe.

[0135] Functional test results:

[0136] Weight gain results Figure 4 As shown in Table 7:

[0137] Table 7 Weight data

[0138] index control group Comparative Example 1 Comparative Example 2 Example 3 group SEM P-value Day 0 8.51 8.52 8.50 8.50 0.01 0.81 Day 21 8.50 b ]] <![CDATA[8.59 a ]]> 8.60 a ]]> <![CDATA[8.62 a ]]> 0.02 ≤0.05 Day 42 <![CDATA[8.56 b ]]> <![CDATA[8.69 a ]]> <![CDATA[8.68 a ]]> 8.74 a ]] 0.02 ≤0.05

[0139] like Figure 4 As shown in Table 7, there was no significant difference in the body weight of the dogs in each test group on day 0 (P>0.05), which reflects the consistency of the weight of the animals at the beginning of the experiment. Compared with the control group, the body weights of the comparative example 1 group, the comparative example 2 group and the embodiment 3 group on days 21 and 42 were significantly increased (P≤0.05), indicating that the comparative example 1 group, the comparative example 2 group and the embodiment 3 group can improve the growth status of the dogs. There was no significant difference in the body weight of the dogs in the comparative example 1 group, the comparative example 2 group and the embodiment 3 group on days 21 and 42 (P>0.05), indicating that the comparative example 1 group, the comparative example 2 group and the embodiment 3 group have the same effect in improving the growth status of the experimental dogs.

[0140] Evaluate according to the stool scoring table (see Figure 2 ), the results are as follows Figure 5 As shown in Table 8:

[0141] Table 8 Stool Scores

[0142] index control group Comparative Example 1 Comparative Example 2 Example 3 group SEM P-value Day 0 5.95 5.87 5.60 5.77 0.11 0.66 Day 21 <![CDATA[5.98 b ]]> <![CDATA[7.05 a ]]> <![CDATA[5.78 b ]]> <![CDATA[7.13 a ]]> 0.15 ≤0.05 Day 42 <![CDATA[6.08 c ]]> 7.75 a ]]> <![CDATA[6.72 b ]]> 7.78 a ]] 0.17 ≤0.05

[0143] like Figure 5 As shown in Table 8, there was no significant difference in the fecal scores of the dogs in each test group on day 0 (P>0.05), indicating that when the test started, each treatment group was at the same intestinal health level. Compared with the control group and the comparative example 2 group, the feces of the comparative example 1 group and the embodiment 3 group on the 21st day were better (P≤0.05), indicating that the comparative example 1 group and the embodiment 3 group can improve the fecal state and intestinal health of the dog. Compared with the control group, the feces of the comparative example 1 group, the comparative example 2 group and the embodiment 3 group on the 42nd day were better (P≤0.05), indicating that the comparative example 1 group, the comparative example 2 group and the embodiment 3 group can improve the fecal state and intestinal health of the dog. Compared with the comparative example 2 group, the feces of the comparative example 1 group and the embodiment 3 group on the 42nd day were better (P≤0.05), indicating that the effect of the comparative example 1 group and the embodiment 3 group on improving the fecal state and intestinal health of the dog is better than the comparative example 2 group. In addition, there was no significant difference in stool scores between the comparative example 1 group and the example 3 group on the 21st and 42nd days (P>0.05), indicating that the two groups had the same effect in improving the fecal status of dogs.

[0144] Fecal odor results such as Figure 6 As shown in Table 9:

[0145] Table 9 Fecal odor

[0146] index control group Comparative Example 1 Comparative Example 2 Example 3 group SEM P-value Day 0 2.13 2.13 2.85 2.12 0.17 0.38 Day 21 2.35 1.60 2.53 1.43 0.18 0.06 Day 42 2.23 1.00 2.27 0.68 0.29 0.09

[0147] Fecal odor is an important indicator of dog intestinal health. When a dog has indigestion or gastrointestinal dysfunction, the ammonia content in the feces will increase. Figure 6 As shown in Table 9 , there was no significant difference in fecal ammonia content among the treatment groups on days 0, 21, and 42 (P>0.05), indicating that all treatment groups were at the same intestinal health level during the experiment.

[0148] Inflammatory markers: Serum levels of tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), lipopolysaccharide (LPS), diamine oxidase (DAO), and fatty acid binding protein (i-FABP) were measured using commercially available kits by ELISA according to the manufacturer's instructions.

[0149] Intestinal inflammation index results such as Figure 7 As shown in Table 10:

[0150] Table 10 Inflammation index results

[0151]

[0152]

[0153] Under normal circumstances, the levels of pro-inflammatory and anti-inflammatory cytokines are balanced, maintaining a certain degree of resistance to pathogen invasion. In canine inflammatory bowel disease, abnormal expression of inflammatory cytokines occurs, such as the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, and the anti-inflammatory cytokine IL-10. In this experiment, there was no significant difference in the IL-6 content among the various experimental groups (P>0.05), indicating that the effect of this inflammatory factor in this experiment was not obvious; for IL-1β, the content of the control group was significantly higher than that of the comparative example 1 group and the example 3 group (P≤0.05), which shows that compared with the control group, the comparative example 1 group and the example 3 group can reduce the inflammation level and promote intestinal health; there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05), indicating that the comparative example 1 group and the example 3 group have the same effect in reducing the inflammation level and promoting intestinal health; in addition, there was no significant difference between the comparative example 2 group and the control group, and between the comparative example 1 group and the example 3 group (P>0.05), indicating that the comparative example 2 group has no obvious effect in reducing the inflammation level and promoting intestinal health. IL-10 is an anti-inflammatory factor, and a decrease in IL-10 content will cause an increase in the level of inflammation. In this experiment, the IL-10 content of the control group and the comparative example 2 group was significantly higher than that of the comparative example 1 group and the example 3 group (P≤0.05), and there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05), which shows that the inflammation levels of the comparative example 1 group and the example 3 group were improved compared with the control group and the comparative example 2 group. The TNF-α content of the control group was significantly higher than that of the comparative example 1 group, the comparative example 2 group and the example 3 group (P≤0.05), and the TNF-α content of the comparative example 2 group was significantly higher than that of the comparative example 1 group and the example 3 group (P≤0.05), while there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05). This shows that the comparative example 1 group, the comparative example 2 group and the example 3 group can reduce the inflammatory level and promote intestinal health, but the effect of the comparative example 1 group and the example 3 group is better than that of the comparative example 2 group.

[0154] LPS is a unique component in the cell wall of Gram-negative bacteria. The LPS content in serum can reflect intestinal inflammation and health status. LPS in serum is usually present at very low levels. It can activate mononuclear macrophages, endothelial cells, epithelial cells, etc. through the cell signal transduction system in the body, synthesize and release a variety of cytokines and inflammatory mediators, and then cause a series of reactions in the body. In the experiment, the LPS content in the control group and the comparative example 2 group was significantly higher than that in the comparative example 1 group and the example 3 group (P≤0.05), while there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05), which shows that the level of inflammation in the control group and the comparative example 2 group was higher than that in the comparative example 1 group and the example 3 group. DAO is located in the cytoplasm of the villi epithelial cells in the upper layer of the intestinal mucosa. Under normal circumstances, the DAO content in serum is very low. When the intestinal epithelial cells are damaged, the DAO in the intestinal mucosa can enter the blood through the damaged site, so the serum DAO level can be used as an ideal indicator for evaluating intestinal barrier damage. In this experiment, the DAO content in the control group and the comparative example 2 group was significantly higher than that in the comparative example 1 group and the example 3 group (P≤0.05), and there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05), which indicates that the degree of intestinal barrier damage in the control group and the comparative example 2 group was higher than that in the comparative example 1 group and the example 3 group. Oxidative stress is associated with the progression of various inflammatory diseases including colitis. MDA is a marker of lipid peroxidation. MDA destroys membrane proteins through denaturation and cross-linking, making them unable to function as receptors or enzymes. On the 42nd day, the MDA content in the control group was significantly higher than that in the comparative example 1 group, the comparative example 2 group and the example 3 group (P≤0.05), and the MDA content in the comparative example 2 group was significantly higher than that in the comparative example 1 group and the example 3 group (P≤0.05), while there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05), indicating that the oxidative stress in the control group was higher than that in the comparative example 1 group, the comparative example 2 group and the example 3 group, while the oxidative stress in the comparative example 2 group was higher than that in the comparative example 1 group and the example 3 group. When intestinal mucosal damage occurs, the location of i-FABP in the mature epithelium of the villi facilitates its leakage from the intestinal cells into the circulation. Measurement of plasma i-FABP concentration is a highly specific and sensitive method for assessing the degree of intestinal mucosal damage. In this experiment, the i-FABP content in the control group was significantly higher than that in the comparative example 1 group and the example 3 group (P≤0.05), and there was no significant difference in the i-FABP content between the comparative example 2 group and the control group, the comparative example 1 group and the example 3 group (P>0.05), which indicates that the degree of intestinal mucosal damage in the control group was higher than that in the comparative example 1 group and the example 3 group.

[0155] Short-chain fatty acids (SCFAs) were determined by gas chromatography. One gram of fecal sample was placed in 15 mL of double-distilled water and stirred thoroughly with a glass rod to dissolve the feces into a homogeneous suspension. The suspension was then sonicated for 30 minutes and centrifuged at 12,000 × g for 10 minutes. The supernatant was filtered through a 0.22 μm filter and collected. One μL of the supernatant was injected onto a capillary column (60 m × 250 μm × 0.25 μm) with cyanopropylmethyl silicone as the stationary phase. The injection port and detector temperatures were maintained at 240°C. Nitrogen was used as the carrier gas at a flow rate of 2.0 mL / min. The peak areas of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, and hexanoic acid were substituted into the regression equation of a calibration curve prepared using the standard to obtain data.

[0156] The results of short-chain fatty acid indicators in the intestine are as follows Figure 8 As shown in Table 11:

[0157] Table 11 Short-chain fatty acid index results

[0158]

[0159]

[0160] SCFAs are important signals that regulate the complex interactions between the host and intestinal microorganisms. They play an important role in maintaining the normal function of the large intestine and the morphology and function of colonic epithelial cells and are regulated by changes in the composition of intestinal microorganisms. Acetic acid, butyric acid, and propionic acid are the main SCFAs produced after the fermentation of dietary carbohydrates. The results showed that in this experiment, the concentration of acetic acid in the feces of Comparative Example 1, Comparative Example 2, and Example 3 groups was significantly higher than that of the control group (P≤0.05), and the concentration of acetic acid in Comparative Example 1 group was significantly higher than that of Comparative Example 2 group (P≤0.05), while there was no significant difference between Example 3 group and Comparative Example 1 group and Comparative Example 2 group (P>0.05). The concentration of butyric acid in the feces of Comparative Example 1 and Example 3 groups was significantly higher than that of the control group and Comparative Example 2 group (P≤0.05). The levels of propionic acid, isobutyric acid, valeric acid, isovaleric acid, and hexanoic acid did not change among the treatment groups (P>0.05). The primary mechanism for altering SCFA composition involves changes in the intestinal microbiome. These results may be due in part to AVA-induced increases in the abundance of acetic acid- or butyric acid-producing bacteria. Acetic acid can serve as a source of butyric acid synthesis, so elevated acetic acid levels can further lead to increased butyric acid content. Butyric acid inhibits the activation of nuclear factor-κB, reduces the production of inflammatory factors, and thus alleviates local intestinal inflammatory responses. Therefore, the experiments demonstrated that both Comparative Example 1 and Example 3 exhibited anti-inflammatory and anti-allergic effects.

[0161] Microbiological indicators:

[0162] The collected dog fecal samples were sequenced using the Illumina Hiseq high-throughput sequencing platform for 16S rRNA sequencing. Figures 9 to 11 As shown:

[0163] At door level ( Figure 9 ), the dominant bacteria in the control group were Firmicutes (94.6%), Actinobacteriota (4.2%), Proteobacteria (0.8%) and Bacteroidota (0.3%); the dominant bacteria in the comparative example group were Firmicutes (89.9%), Actinobacteriota (4.2%), Bacteroidota (4.1%) and Proteobacteria (0.8%). The dominant bacteria in Example 3 group were Firmicutes (95.3%), Actinobacteriota (2.3%), Proteobacteria (1.3%) and Bacteroidota (0.4%).

[0164] At the scientific level ( Figure 10),对照组的优势菌为Peptostreptococcaceae(55.4%)、Lachnospiraceae(11.9%)、Streptococcaceae(6.0%)、Clostridiaceae(6.8%)、Enterococcaceae(2.0%)、Erysipelotrichaceae(3.9%)、Coriobacteriaceae(3.2%)、Leuconostocaceae(4.5%)、Lactobacillaceae(1.1%)、Prevotellaceae(0.2%)和Erysipelatoclostridiaceae(1.4%);对比例组的优势菌为Peptostreptococcaceae(56.4%)、Lachnospiraceae(9.8%)、Streptococcaceae(9.5%)、Clostridiaceae(1.8%)、Enterococcaceae(0.2%)、Erysipelotrichaceae(2.6%)、Coriobacteriaceae(3.3%)、Leuconostocaceae(0.7%)、Lactobacillaceae(5.0%)、Prevotellaceae(2.8%)和Erysipelatoclostridiaceae(0.8%);实施例3组的优势菌为Peptostreptococcaceae(54.3%)、Lachnospiraceae(15.5%)、Streptococcaceae(0.6%)、Clostridiaceae(4.5%)、Enterococcaceae(8.6%)、Erysipelotrichaceae(2.1%)、Coriobacteriaceae(2.0%)、Leuconostocaceae(2.6%)、Lactobacillaceae(0.2%)、Prevotellaceae(20.9%)和Erysipelatoclostridiaceae(0.7%)。

[0165] 在属水平上( Figure 11),对照组的优势菌为Peptoclostridium(52.2%)、Blautia(9.2%)、Streptococcus(6.0%)、Clostridium_sensu_stricto_1(6.8%)、Enterococcus(2.0%)、Collinsella(3.2%)、unclassified_f__Peptostreptococcaceae(3.0%)、Weissella(4.1%)、Lactobacillus(1.1%)、Jeotgalibaca(1.1%)、unclassified_f__Lachnospiraceae(1.0%)、Holdemanella(1.8%)、Ruminococcus_gnavus_group(0.2%)、Bacillus(0.3%);对比例组的优势菌为Peptoclostridium(50.9%)、Blautia(7.9%)、Streptococcus(9.5%)、Clostridium_sensu_stricto_1(1.7%)、Enterococcus(0.2%)、Collinsella(3.3%)、unclassified_f__Peptostreptococcaceae(1.4%)、Weissella(0.6%)、Lactobacillus(5.0%)、Romboutsia(4.1%)、unclassified_f__Lachnospiraceae(0.9%)、Holdemanella(0.5%)、Prevotella(2.7%)、Ruminococcus_gnavus_group(0.7%)和Bacillus(1.7%);实施例3组的优势菌为Peptoclostridium(50.9%)、Blautia(11.5%)、Clostridium_sensu_stricto_1(4.5%)、Enterococcus(8.6%)、Collinsella(2.0%)、unclassified_f__Peptostreptococcaceae(2.9%)、Weissella(2.5%)、Romboutsia(0.5%)、Jeotgalibaca(3.2%)、unclassified_f__Lachnospiraceae(1.6%)、Ruminococcus_gnavus_group(1.2%)、Aerococcus(1.5%), Psychrobacter (1.0%). .

[0166] Comparison of microbial richness across the groups revealed that: There was no significant difference in the richness of the family Lachnospiraceae between the control and control groups (P>0.05); the richness of Example 3 was significantly increased in the control group compared with Example 3 (P≤0.05); and there was no significant difference between the control and Example 3 groups (P>0.05). There was no significant difference in the richness of the family Erysipelotrichaceae between the control and control groups (P>0.05); the richness of Example 3 was significantly increased in the control group compared with Example 3 (P≤0.05); and there was no significant difference between the control and Example 3 groups (P>0.05). There was no significant difference in the richness of the genus Blautia between the control and control groups (P>0.05); the richness of Example 3 was significantly increased in the control group compared with Example 3 (P≤0.05); and there was no significant difference between the control and Example 3 groups (P>0.05).

[0167] f__The Lachnospiraceae family is a family of Lachnospiraceae that can hydrolyze starch and other sugars to produce butyrate and other short-chain fatty acids, and has the ability to produce beneficial metabolites.

[0168] f__Erysipelotrichaceae is a family of bacteria in the Erysipelotrichaceae family, Erysipelotrichales order, Actinomycetes. Erysipelotrichaceae microorganisms in the animal intestine can produce short-chain fatty acids (SCFAs), mainly including acetate, propionate and butyrate, which can provide energy for the body and promote metabolism.

[0169] Blautia, a genus of the Lachnospiraceae family, is a strictly anaerobic, non-motile bacterium that is a core bacterial genus in the mammalian intestine. Blautia can use hydrogen and carbon dioxide to produce acetate. Acetate is a secondary energy source for intestinal epithelial cells and an energy source for muscle and brain tissue. It can inhibit pathogens and has anti-inflammatory effects.

[0170] In summary, the combined fiber sheet of Example 3 can increase the richness of beneficial bacteria and improve the intestinal microecology of dogs.

[0171] Conclusion: Example 3 is more effective in increasing the richness of beneficial intestinal bacteria, alleviating intestinal inflammation and protecting intestinal health.

[0172] Although the above embodiment provides a detailed description of the present invention, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the scope of protection of the present invention.

Claims

1. A composition that helps regulate intestinal microorganisms in adult dogs, characterized in that: The invention comprises the following components in parts by weight: 10-30 parts of pea dietary fiber, 10-30 parts of citrus dietary fiber, 10-20 parts of avocado extract, 2-30 parts of oat dietary fiber and 10-15 parts of seaweed dietary fiber.

2. The composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 15-20 parts of pea dietary fiber, 15-20 parts of citrus dietary fiber, 12-18 parts of avocado extract, 17-18 parts of oat dietary fiber and 12-13 parts of seaweed dietary fiber.

3. The composition according to claim 1 or 2, characterized in that Also includes: 2-5 parts of lycopene and 3-6 parts of vitamin C.

4. The composition according to claim 1 or 2, characterized in that The pea dietary fiber includes pea dietary fiber powder; the citrus dietary fiber includes citrus dietary fiber powder; the particle sizes of the pea dietary fiber powder and the citrus dietary fiber powder are independently 180 to 240 μm.

5. A composite fiber sheet that helps regulate intestinal microorganisms in adult dogs, characterized in that: The invention comprises the composition according to any one of claims 1 to 4 and auxiliary materials; based on 10 to 30 parts of pea dietary fiber, the auxiliary materials preferably comprise: 2 to 20 parts of glucose and 2 to 5 parts of edible flavoring.

6. Use of the composition according to any one of claims 1 to 4 or the combined fiber sheet according to claim 5 in the preparation of products for regulating intestinal microorganisms of adult dogs and / or improving the growth status of adult dogs; the products include feed, feed additives, nutritional supplements or medicines.

7. The use according to claim 6, characterized in that The regulation of intestinal microorganisms of adult dogs includes one or more of the aspects 1) to 3): 1) Increase the abundance of beneficial intestinal bacteria; 2) Improve the fecal status of adult dogs; 3) Improve the fecal odor of adult dogs.

8. The use according to claim 7, characterized in that The beneficial bacteria include one or more of the Lachnospiraceae family, the Erysipelotrichaceae family and the Blautia genus.

9. Use of the composition according to any one of claims 1 to 4 or the combined fiber sheet according to claim 5 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease in adult dogs.

10. The use according to claim 9, characterized in that The prevention and / or treatment of inflammatory bowel disease in adult dogs includes one or more of the aspects (1) to (4): (1) Reduce intestinal inflammation levels; (2) Repair intestinal mucosal damage; (3) Reduce oxidative stress in the intestine; (4) Increase the content of short-chain fatty acids in the intestine.

Images